Abstract
Atherosclerotic cardiovascular disease (ASCVD) contributes to morbidity and mortality in systemic lupus erythematosus (SLE). Immunologic derangements may disrupt cholesterol balance in vessel wall monocytes/macrophages and endothelium. We determined whether lupus plasma impacts expression of cholesterol 27-hydroxylase, an anti-atherogenic cholesterol-degrading enzyme that promotes cellular cholesterol efflux, in THP-1 human monocytes and primary human aortic endothelial cells (HAEC). THP-1 monocytes and HAEC were incubated in medium containing SLE patient plasma or apparently healthy control human plasma (CHP). SLE plasma decreased 27-hydroxylase message in THP-1 monocytes by 47 ± 8% (p < 0.008) and in HAEC by 51 ± 5.5% (n = 5, p < 0.001). THP-1 macrophages were incubated in 25% lupus plasma or CHP and cholesterol-loaded (50 µg ml−1 acetylated low density lipoprotein). Lupus plasma more than doubled macrophage foam cell transformation (74 ± 3% vs. 35 ± 3% for CHP, n = 3, p < 0.001). Impaired cholesterol homeostasis in SLE provides further evidence of immune involvement in atherogenesis. Strategies to inhibit or reverse arterial cholesterol accumulation may benefit SLE patients.
Similar content being viewed by others
References
Asanuma Y, Oeser A, Shintani AK et al (2003) Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 349:2407–2415
Roman MJ, Shanker BA, Davis A et al (2003) Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 349:2399–2406
Nikpour M, Urowitz MB, Gladman DD (2005) Premature atherosclerosis in systemic lupus erythematosus. Rheum Dis Clin North Am 31:329–354
Schattner A, Liang MH (2003) The cardiovascular burden of lupus: a complex challenge. Arch Intern Med 163:1507–1510
Bruce IN, Gladman DD, Urowitz MB (2000) Premature atherosclerosis in systemic lupus erythematosus. Rheum Dis Clin North Am 26:257–278
Manzi S, Meilahn EN, Rairie JE et al (1997) Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 145:408–415
Badui E, Garcia-Rubi D, Robles E et al (1985) Cardiovascular manifestations in systemic lupus erythematosus. Prospective study of 100 patients. Angiology 36:431–441
Moder KG, Miller TD, Tazelaar HD (1999) Cardiac involvement in systemic lupus erythematosus. Mayo Clin Proc 74:275–284
Caracciolo EA, Marcu CB, Ghantous A, Donohue TJ, Hutchinson G (2004) Coronary vasculitis with acute myocardial infarction in a young woman with systemic lupus erythematosus. J Clin Rheumatol 10:66–68
Nobrega TP, Klodas E, Breen JF, Liggett SP, Higano ST, Reeder GS (1996) Giant coronary artery aneurysms and myocardial infarction in a patient with systemic lupus erythematosus. Cathet Cadiovasc Diagn 39:75–79
Sharma AK, Farb A, Maniar P, Ajani AE, Castagna M, Virmani R, Suddath W, Lindsay J (2003) Spontaneous coronary artery dissection in a patient with systemic lupus erythematosis. Hawaii Med J 62:248–253
Sella EM, Sato EI, Leite WA, Oliveira Filho JA, Barbieri A (2003) Myocardial perfusion scintigraphy and coronary disease risk factors in systemic lupus erythematosus. Ann Rheum Dis 62:1066–1070
Soubrier M, Mathieu S, Dubost JJ (2007) Atheroma and systemic lupus erythematosus. Joint Bone Spine 74:566–570
Libby P, Ridker PM, Maseri A (2002) Inflammation and atherosclerosis. Circulation 105:1135–1143
Roman MJ, Salmon JE, Sobel R, Lockshin MD, Sammaritano L, Schwartz JE, Devereux RB (2001) Prevalence and relation to risk factors of carotid atherosclerosis and left ventricular hypertrophy in systemic lupus erythematosus and antiphospholipid syndrome. Am J Cardiol 87:663–666
Gezer S (2003) Antiphospholipid syndrome. Dis Mon 49:696–741
Lahita RG, Rivkin E, Cavanagh I et al (1993) Low levels of total cholesterol, high-density lipoprotein, and apolipoprotein A1 in association with anticardiolipin antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 36:1566–1574
Vaarala O, Alfthan G, Jauhiainen M et al (1993) Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 341:923–925
Garrido JA, Peromingo J, Sesma P et al (1994) More about the link between thrombosis and atherosclerosis in autoimmune diseases: triglycerides and risk for thrombosis in patients with antiphospholipid antibodies. J Rheumatol 21:2394
Esdaile JM, Abrahamowicz M, Grodzicky T et al (2001) Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 44:2331–2337
Fukumoto S, Tsumagari T, Kinjo M et al (1987) Coronary atherosclerosis in patients with systemic lupus erythematosus at autopsy. Acta Pathol Jpn 37:1–9
Haider YS, Roberts WC (1981) Coronary arterial disease in systemic lupus erythematosus. Am J Med 70:775–781
Reiss AB, Awadallah NW, Malhotra S et al (2001) Immune complexes and interferon-γ decrease cholesterol 27-hydroxylase in human arterial endothelium and macrophages. J Lipid Res 42:1913–1922
Reiss AB, Patel CA, Rahman MM et al (2004) Interferon-gamma impedes reverse cholesterol transport and promotes foam cell transformation in THP-1 human monocytes/macrophages. Med Sci Monit 10:BR420–BR425
Hall EA, Ren S, Hylemon PB, Redford K, del Castillo A, Gil G, Pandak WM (2005) Mitochondrial cholesterol transport: a possible target in the management of hyperlipidemia. Lipids 40:1237–1244
Reiss AB, Martin KO, Javitt NB, Martin DW, Grossi EA, Galloway AC (1994) Sterol 27-hydroxylase: high levels of activity in vascular endothelium. J Lipid Res 35:1026–1030
Reiss AB, Martin KO, Rojer DE, Iyer S, Grossi EA, Galloway AC, Javitt NB (1997) Sterol 27-hydroxylase: expression in human arterial endothelium. J Lipid Res 38:1254–1260
Fuster V, Badimon L, Badimon JJ, Chesebro JH (1992) The pathogenesis of coronary artery disease. N Engl J Med 326:242–250
Badimon L, Badimon JJ, Penny W, Webster MW, Chesebro JH, Fuster V (1992) Endothelium and atherosclerosis. J Hypertens Suppl 10:S43–S50
Zeiher AM, Drexler H, Saurbier B, Just H (1993) Endothelium-mediated coronary blood flow modulation in humans: effects of age, atherosclerosis, hypercholesterolemia, and hypertension. J Clin Invest 92:652–662
Marchesi S, Lupattelli G, Siepi D, Schillaci G, Vaudo G, Roscini AR, Sinzinger H, Mannarino E (2000) Short-term atorvastatin treatment improves endothelial function in hypercholesterolemic women. J Cardiovasc Pharmacol 36:617–621
Bjorkhem I (2002) Do oxysterols control cholesterol homeostasis. J Clin Invest 110:725–730
Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277
Chan ES, Zhang H, Fernandez P, Edelman SD, Pillinger MH, Ragolia L, Palaia T, Carsons SE, Reiss AB (2007) Effect of COX inhibition on cholesterol efflux proteins and atheromatous foam cell transformation in THP-1 human macrophages: a possible mechanism for increased cardiovascular risk. Arthritis Res Ther 9:R4
Cali JJ, Hsieh C, Francke U, Russell DW (1991) Mutations in the bile acid biosynthetic enzyme sterol 27-hydroxylase underlie cerebrotendinous xanthomatosis. J Biol Chem 266:7779–7783
Reiss AB, Glass AD (2006) Atherosclerosis: immune and inflammatory aspects. J Invest Med 54:123–131
Moore KJ, Freeman MW (2006) Scavenger receptors in atherosclerosis: beyond lipid uptake. Arterioscler Thromb Vasc Biol 26:1702–1711
McMahon M, Hahn BH (2007) Atherosclerosis and systemic lupus erythematosus: mechanistic basis of the association. Curr Opin Immunol 19:633–639
Al-Janadi M, Al-Balla S, Al-Dalaan A, Raziuddin S (1993) Cytokine profile in systemic lupus erythematosus, rheumatoid arthritis and other rheumatic diseases. J Clin Immunol 13:58–67
Aringer M, Smolen JS (2004) Tumour necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic intervention. Lupus 13:344–347
Asanuma Y, Chung CP, Oeser A, Shintani A, Stanley E, Raggi P, Stein CM (2006) Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: relationship to cardiovascular risk factors. J Rheumatol 33:539–545
Gautier EL, Huby T, Ouzilleau B, Doucet C, Saint-Charles F, Gremy G, Chapman MJ, Lesnik P (2007) Enhanced immune system activation and arterial inflammation accelerates atherosclerosis in lupus-prone mice. Arterioscler Thromb Vasc Biol 27:1625–1631
Reiss AB, Wan DW, Anwar K, Merrill JT, Wirkowski PA, Shah N, Cronstein BN, Chan ES, Carsons SE (2009) Enhanced CD36 scavenger receptor expression in THP-1 human monocytes in the presence of lupus plasma: linking autoimmunity and atherosclerosis. Exp Biol Med 234:354–360
Gupta S, Pablo AM, Jiang X, Wang N, Tall AR, Schindler C (1997) IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. J Clin Invest 99:2752–2761
Li H, Freeman MW, Libby P (1995) Regulation of smooth muscle cell scavenger receptor expression in vivo by atherogenic diets and in vitro by cytokines. J Clin Invest 95:122–133
Whitman SC, Ravisankar P, Elam H, Daugherty A (2000) Exogenous interferon-gamma enhances atherosclerosis in apolipoprotein E−/− mice. Am J Pathol 157:1819–1824
Lund E, Andersson O, Zhang J, Babiker A, Ahlborg G, Diczfalusy U, Einarsson K, Sjovall J, Bjorkhem I (1996) Importance of a novel oxidative mechanism for elimination of intracellular cholesterol in humans. Arterioscler Thromb Vasc Biol 16:208–212
Reiss AB, Anwar F, Chan ESL, Anwar K (2009) Disruption of cholesterol efflux by coxib medications and inflammatory processes: link to increased cardiovascular risk. J Invest Med [Epub ahead of print]
Reiss AB, Carsons SE, Rao S, Edelman SD, Zhang H, Fernandez P, Cronstein BN, Chan ES (2008) Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in THP-1 human monocytes/macrophages. Arthritis Rheum 58:3675–3683
Kabokov AE, Tertov VV, Saenko VA, Poverenny AM, Orekhov AN (1992) The atherogenic effect of lupus sera: systemic lupus erythematosus-derived immune complexes stimulate the accumulation of cholesterol in cultured smooth muscle cells from human aorta. Clin Immunol Immunopathol 6:214–220
Matsuura E, Lopez LR (2004) Are oxidized LDL/beta2-glycoprotein I complexes pathogenic antigens in autoimmune-mediated atherosclerosis? Clin Dev Immunol 11:103–111
Acknowledgments
We thank Mr. Alexander Schoen for his technical assistance in manuscript design and assembly. This work was supported by an Innovative Research Grant from the Arthritis Foundation, National Center and by a grant from The National Institutes of Health/National Heart, Lung and Blood Institute HL073814 (Reiss). Additional support was provided by the Arthritis Foundation, New York Chapter and the Scleroderma Foundation (Chan), the National Institutes of Health (AR41911, AA13336 and GM56268), and the General Clinical Research Center (M01RR00096) (Cronstein).
Conflict of interest statement
All authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Reiss, A.B., Anwar, K., Merrill, J.T. et al. Plasma from systemic lupus patients compromises cholesterol homeostasis: a potential mechanism linking autoimmunity to atherosclerotic cardiovascular disease. Rheumatol Int 30, 591–598 (2010). https://doi.org/10.1007/s00296-009-1020-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-009-1020-6